These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 36891744)

  • 1. CAR T-cell treatment of high-risk multiple myeloma: will there be a cure?
    Gahrton G
    Haematologica; 2023 Oct; 108(10):2568-2569. PubMed ID: 36891744
    [No Abstract]   [Full Text] [Related]  

  • 2. CAR T-cell therapy against B-cell maturation antigen in multiple myeloma.
    Cohen AD
    Clin Adv Hematol Oncol; 2018 Dec; 16(12):804-806. PubMed ID: 30843888
    [No Abstract]   [Full Text] [Related]  

  • 3. Impact of high-risk disease on the efficacy of chimeric antigen receptor T-cell therapy for multiple myeloma: a meta-analysis of 723 patients.
    Gagelmann N; Ayuk FA; Klyuchnikov E; Wolschke C; Berger SC; Kröger N
    Haematologica; 2023 Oct; 108(10):2799-2802. PubMed ID: 36815380
    [No Abstract]   [Full Text] [Related]  

  • 4. Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma.
    Ma T; Shi J; Liu H
    Ann Hematol; 2019 Apr; 98(4):813-822. PubMed ID: 30693373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric Antigen Receptor T-Cell Therapeutics for Multiple Myeloma: Moving Into the Spotlight.
    Wang B; Rajeeve S; Madduri D
    Cancer J; 2021 May-Jun 01; 27(3):205-212. PubMed ID: 34549909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric Antigen Receptor T Cells in Multiple Myeloma.
    Shah P; Sperling AS
    Hematol Oncol Clin North Am; 2023 Dec; 37(6):1089-1105. PubMed ID: 37563077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
    Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
    Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple Myeloma, Targeting B-Cell Maturation Antigen With Chimeric Antigen Receptor T-Cells.
    Shah UA; Smith EL
    Cancer J; 2019; 25(3):208-216. PubMed ID: 31135528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Driving CARs to new places: locally produced BCMA CAR T cells to treat multiple myeloma.
    Sjöstrand M; Sadelain M
    Haematologica; 2023 Jul; 108(7):1721-1723. PubMed ID: 36794501
    [No Abstract]   [Full Text] [Related]  

  • 10. Subsequent anti-myeloma therapy after maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cell (HDS269B) treatment in patients with relapsed/refractory multiple myeloma.
    Chen D; Wang X; Chen Z; Jiang S; Jiang H; Fu W; Xiang F; Sun X; Du J
    Am J Hematol; 2022 Dec; 97(12):E478-E481. PubMed ID: 36197023
    [No Abstract]   [Full Text] [Related]  

  • 11. CAR T cell therapy for multiple myeloma: where are we now and where are we headed?
    Ghosh A; Mailankody S; Giralt SA; Landgren CO; Smith EL; Brentjens RJ
    Leuk Lymphoma; 2018 Sep; 59(9):2056-2067. PubMed ID: 29105517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perspectives for the Use of CAR-T Cells for the Treatment of Multiple Myeloma.
    Jasiński M; Basak GW; Jedrzejczak WW
    Front Immunol; 2021; 12():632937. PubMed ID: 33717171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chimeric antigen receptor T-cell therapy for multiple myeloma].
    Hosen N
    Rinsho Ketsueki; 2021; 62(6):619-623. PubMed ID: 34219089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells.
    Karschnia P; Miller KC; Yee AJ; Rejeski K; Johnson PC; Raje N; Frigault MJ; Dietrich J
    Blood; 2023 Oct; 142(14):1243-1248. PubMed ID: 37471607
    [No Abstract]   [Full Text] [Related]  

  • 15. Determinants of response and mechanisms of resistance of CAR T-cell therapy in multiple myeloma.
    van de Donk NWCJ; Themeli M; Usmani SZ
    Blood Cancer Discov; 2021 Jul; 2(4):302-318. PubMed ID: 34386775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CAR T cell therapy for multiple myeloma.
    Barranco C
    Nat Cancer; 2023 Dec; 4(12):1644. PubMed ID: 38102351
    [No Abstract]   [Full Text] [Related]  

  • 17. Immune-mediated facial nerve paralysis in a myeloma patient post B-cell maturation antigen-targeted chimeric antigen receptor T cells.
    Kathari YK; Ahmad H; Kallen ME; Koka R; Omili D; Iraguha T; Clement J; Pham L; Khalid M; Fan X; Gebru E; Lesho P; Park E; Dishanthan N; Baker JM; Dietze KA; Hankey KG; Badros A; Yared JA; Dahiya S; Hardy NM; Kocoglu H; Luetkens T; Rapoport AP; Atanackovic D
    Haematologica; 2024 Feb; 109(2):682-688. PubMed ID: 37675514
    [No Abstract]   [Full Text] [Related]  

  • 18. [Treatment of two cases of extramedullary infiltration multiple myeloma with BCMA CAR-T cells].
    Sun YJ; Liu XC; Han L; Wu SS; Liu YY; Gao QL; Song YP; Zhou KS
    Zhonghua Xue Ye Xue Za Zhi; 2021 Mar; 42(3):253-255. PubMed ID: 33910313
    [No Abstract]   [Full Text] [Related]  

  • 19. Optimizing the benefits of BCMA-targeted CAR T-cell therapy in multiple myeloma.
    Lonial S
    Clin Adv Hematol Oncol; 2023 Jan; 21(1):43-45. PubMed ID: 36638355
    [No Abstract]   [Full Text] [Related]  

  • 20. [CAR-T cells immunotherapy in multiple myeloma: Present and future].
    Ferment B; Arnulf B
    Bull Cancer; 2021 Oct; 108(10S):S65-S72. PubMed ID: 34920809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.